British Airways Reveals its Top Ten Destinations for 2011

British Airways reveals its top ten destinations for 2011, with the US, Caribbean and Indian Ocean being contenders but Marrakech in North Africa taking pride of place.

2010-12-12

WEST SUSSEX, ENGLAND, December 12, 2010 (Press-News.org) British Airways has announced that the US, Caribbean and Indian Ocean all feature heavily in its top ten destinations for 2011, but the pride of place goes to North African destination, Marrakech.

Willie Walsh, British Airways' CEO, said: "The response we've had to the launch of routes like the Maldives, Las Vegas and Marrakech has been incredible. We've seen destinations in the Caribbean and Indian Ocean becoming even more popular with leisure travellers looking for sun and relaxation. Those after 24-hour cities are heading towards New York, Las Vegas and Japan."

He added: "Tourism and leisure travel is a crucial focus for us, so growing our holidays business is a major part of our business plan. We've already made great progress thanks to the launch of our Dynamic Packaging capability on ba.com, which enables customers to book flights and hotels together and realise substantial savings. Revenue this year is up 55 per cent and there remains a huge opportunity for future growth."

BA's top ten destinations for 2011 also includes the airline's new routes, with services to Haneda (Tokyo) starting on February 19, Marrakech beginning on March 27, Puerto Rico on March 28, and flights to San Diego on June 1, 2011.

British Airways top ten destinations include Marrakech at the number one spot, followed by San Diego, New York, St Kitts & Nevis, Puerto Rico, Maldives, Japan, Las Vegas, Mauritius and St Lucia.

British Airways joint business with American Airlines and Iberia also gives customers a choice of 17 flights a day between London and New York.

About British Airways:
British Airways plc offers a wide range of worldwide destinations - including Caribbean holidays, hotels in Marrakech, flights, car hire and experiences. Customers can save time and money with ba.com when booking ATOL protected holiday packages, ATOL number is 5985. Passengers are offered added peace of mind to their holiday plans and the security of travelling with British Airways. British Airways plc constantly seeks to exceed customers' expectations, both in terms of the value for money and quality of the service provided.

Website: http://www.ba.com

ELSE PRESS RELEASES FROM THIS DATE:

Topshop Launches Christmas Fashion Film

2010-12-12

Topshop has launched its new Christmas fashion film, which highlights the key trends for this year's Christmas period and the party season. The festive fashion film is directed by Angelo Pennetta and features model Ashley Smith and stylist Francesca Burns showing off the hottest pieces for the Christmas period this year. The video helps Christmas party-goers create some beautiful looks, whether they plan to stay in with friends or head out on the town. Some of the keys trends this season include diamante scattered fishtail gown and sequin shift dresses which ...

Scientists trace origin of recent cholera epidemic in Haiti

2010-12-11

The strain of cholera currently sweeping through post-earthquake Haiti originated in South Asia, conclude scientists who did a rapid genetic analysis of bacteria collected from Haitian patients. The finding supports the notion that the cholera bacteria fueling the outbreak arrived on the island via recent visitors. "The mostly likely explanation for the sudden appearance of cholera in Haiti is transmission of V. cholera by an infected human, food, or other contaminated item from a region outside of Latin America to Haiti," conclude Howard Hughes Medical Institute (HHMI) ...

The importance of making a good first impression in the classroom

2010-12-11

MAYWOOD, Ill. -- A study of how medical students evaluate their professors is illustrating the critical importance of making a good first impression. Students in a physiology course at Loyola University Chicago Stritch School of Medicine were asked to evaluate 16 professors who lectured during the course. Students had the option of evaluating each professor concurrently during the course, or waiting until the course ended. Students were allowed to change their minds before the evaluations were finalized at the end of the course. The study, published in the December, 2010 ...

First kidney paired donor transplants performed

2010-12-11

LEBANON, NH - Kathy Niedzwiecki of Pelham, NH, and Ken Crowder of St. Louis are experiencing renewed life and health thanks to the generosity of two living kidney donors. Cathy Richard of Henniker, NH, had planned to donate to her sister-in-law, Ms. Niedzwiecki, and Rebecca Burkes of St. Louis had intended to be a living donor for her fiancé, Mr. Crowder – only to find that both were medically incompatible with their intended recipient. But in the first paired donation arranged through a national pilot program of the Organ Procurement and Transplantation Network (OPTN), ...

Combination therapy reduced HER2-positive breast cancers

2010-12-11

SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT. Reporters who cannot attend in person can participate using the following call-in information: U.S. and Canada: (888) 282-7404 International: (706) 679-5207 Access Code: ...

Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

2010-12-11

SAN ANTONIO — Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic ...

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

2010-12-11

SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial. Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "The findings establish that the addition of pertuzumab to trastuzumab and the chemotherapy drug docetaxel has an impressive rate of tumor eradication (46 percent), which is 50 percent more than achieved with docetaxel and trastuzumab, ...

Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer

2010-12-11

SAN ANTONIO — The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment. Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast ...

High CTC levels predicted poor outcome in metastatic breast cancer

2010-12-11

SAN ANTONIO — A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body through the blood — are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level during therapy was found to be an early marker of poor outcome. "This is the largest, prospective series validating the prognostic value of CTCs in first-line chemotherapy metastatic breast cancer, independently from serum tumor markers for overall survival," said Jean-Yves Pierga, M.D., Ph.D., ...

Denosumab delayed time to first skeletal-related side effect

2010-12-11

SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. "The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine ...

British Airways Reveals its Top Ten Destinations for 2011

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: